Literature DB >> 17517872

Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Egídio Torrado1, Sarojini Adusumilli, Alexandra G Fraga, Pamela L C Small, António G Castro, Jorge Pedrosa.   

Abstract

The pathogenicity of Mycobacterium ulcerans, the agent of Buruli ulcer, depends on the cytotoxic exotoxin mycolactone. Little is known about the immune response to this pathogen. Following the demonstration of an intracellular growth phase in the life cycle of M. ulcerans, we investigated the production of tumor necrosis factor (TNF) induced by intramacrophage bacilli of diverse toxigenesis/virulence, as well as the biological relevance of TNF during M. ulcerans experimental infections. Our data show that murine bone marrow-derived macrophages infected with mycolactone-negative strains of M. ulcerans (nonvirulent) produce high amounts of TNF, while macrophages infected with mycolactone-positive strains of intermediate or high virulence produce intermediate or low amounts of TNF, respectively. These results are in accordance with the finding that TNF receptor P55-deficient (TNF-P55 KO) mice are not more susceptible than wild-type mice to infection by the highly virulent strains but are more susceptible to nonvirulent and intermediately virulent strains, demonstrating that TNF is required to control the proliferation of these strains in animals experimentally infected by M. ulcerans. We also show that mycolactone produced by intramacrophage M. ulcerans bacilli inhibits, in a dose-dependent manner, but does not abrogate, the production of macrophage inflammatory protein 2, which is consistent with the persistent inflammatory responses observed in experimentally infected mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517872      PMCID: PMC1951989          DOI: 10.1128/IAI.00290-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  87 in total

Review 1.  Roles of lipoarabinomannan in the pathogenesis of tuberculosis.

Authors:  G R Strohmeier; M J Fenton
Journal:  Microbes Infect       Date:  1999-07       Impact factor: 2.700

2.  Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans.

Authors:  Hui Hong; Paul J Gates; James Staunton; Tim Stinear; Stewart T Cole; Peter F Leadlay; Jonathan B Spencer
Journal:  Chem Commun (Camb)       Date:  2003-11-21       Impact factor: 6.222

3.  Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide.

Authors:  F Y Liew; Y Li; S Millott
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

4.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

Authors:  K M George; D Chatterjee; G Gunawardana; D Welty; J Hayman; R Lee; P L Small
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

5.  High sensitivity of transgenic mice expressing soluble TNFR1 fusion protein to mycobacterial infections: synergistic action of TNF and IFN-gamma in the differentiation of protective granulomas.

Authors:  I Garcia; Y Miyazaki; G Marchal; W Lesslauer; P Vassalli
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

6.  The histopathologic spectrum in Mycobacterium marinum infection.

Authors:  W D Travis; L B Travis; G D Roberts; D W Su; L W Weiland
Journal:  Arch Pathol Lab Med       Date:  1985-12       Impact factor: 5.534

7.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

8.  Chemokine response in mice infected with Mycobacterium tuberculosis.

Authors:  E R Rhoades; A M Cooper; I M Orme
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

9.  Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis.

Authors:  M Denis
Journal:  J Leukoc Biol       Date:  1991-11       Impact factor: 4.962

10.  Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum.

Authors:  N Mor; I Lutsky; L Levy
Journal:  Isr J Med Sci       Date:  1981-04
View more
  41 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation.

Authors:  Laure Guenin-Macé; Romain Veyron-Churlet; Maria-Isabel Thoulouze; Guillaume Romet-Lemonne; Hui Hong; Peter F Leadlay; Anne Danckaert; Marie-Thérèse Ruf; Serge Mostowy; Chiara Zurzolo; Philippe Bousso; Fabrice Chrétien; Marie-France Carlier; Caroline Demangel
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

3.  Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

4.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

Review 5.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

Review 6.  Contrasting persistence strategies in Salmonella and Mycobacterium.

Authors:  Anna D Tischler; John D McKinney
Journal:  Curr Opin Microbiol       Date:  2010-01-06       Impact factor: 7.934

7.  Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion.

Authors:  Charlotte A Huber; Marie-Thérèse Ruf; Gerd Pluschke; Michael Käser
Journal:  Clin Vaccine Immunol       Date:  2008-02-06

Review 8.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

9.  Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.

Authors:  Nicholas J Tobias; Torsten Seemann; Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Estelle Marion; Franck Letournel; Tasnim Zakir; Joseph Azuolas; John R Wallace; Hui Hong; John K Davies; Benjamin P Howden; Paul D R Johnson; Grant A Jenkin; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2009-11-24

10.  Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Paul J Converse; Deepak V Almeida; Jihui Zhang; Clive Robinson; Mark Wansbrough-Jones; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.